The impact of fraudulent and irreproducible data to the translational research crisis – solutions and implementation

Journal of Neurochemistry

Volumn 139, Issue , 2016, Pages 253-270

  Schulz, Jörg B ^a,b   Cookson, Mark R ^c   Hausmann, Laura ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

60th Anniversary Journal of Neurochemistry; clinical trials; data reproducibility; scholarly publishing; statistics

Indexed keywords

ALTEPLASE; MEASLES MUMPS RUBELLA VACCINE; TAR DNA BINDING PROTEIN;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ATTITUDE TO HEALTH; AUTISM; AUTISTIC ENTEROCOLITIS; BASILAR ARTERY; CELL MODEL; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE MODEL; ENTEROCOLITIS; ERROR; EVIDENCE BASED MEDICINE; EXPERIMENTAL DESIGN; FACTUAL DATABASE; FRAUDULENT DATA; GOOD RESEARCH PRACTICE; HUMAN; IMMUNIZATION; INFORMATION; INTERNAL VALIDITY; IRREPRODUCIBLE DATA; MEDICAL ETHICS; MEDICAL LITERATURE; META ANALYSIS (TOPIC); METHODOLOGY; MIDDLE CEREBRAL ARTERY; MOLECULAR MODEL; MUTATIONAL ANALYSIS; NERVE CELL DIFFERENTIATION; NEUROCHEMISTRY; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT SELECTION; PERCUTANEOUS THROMBECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; PUBLISHING; QUALITY CONTROL; RANKIN SCALE; REPORTING BIAS; REPRODUCIBILITY; SCIENTIFIC MISCONDUCT; SINGLE NUCLEOTIDE POLYMORPHISM; SOD1 GENE; STATISTICAL ANALYSIS; STUDY DESIGN; TRANSGENIC MOUSE; TRANSLATIONAL RESEARCH; ANIMAL; STANDARDS; STATISTICS; TRENDS;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; REPRODUCIBILITY OF RESULTS; SCIENTIFIC MISCONDUCT; STATISTICS AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84993990232     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13844     Document Type: Article

References (64)

1. Allen M., Bjerke M., Edlund H., Nelander S. and Westermark B. (2016) Origin of the U87MG glioma cell line: good news and bad news. Sci. Transl. Med. 8, 354re353.
2. Al-Shahi Salman R., Beller E., Kagan J., Hemminki E., Phillips R. S., Savulescu J., Macleod M., Wisely J. and Chalmers I. (2014) Increasing value and reducing waste in biomedical research regulation and management. The Lancet 383, 176–185.
3. Baker M. (2016) 1,500 scientists lift the lid on reproducibility. Nature News 533, 452–454.
4. Bensimon G., Lacomblez L. and Meininger V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N. Engl. J. Med. 330, 585–591.
5. Berkhemer O. A., Fransen P. S., Beumer D. et al. (2015) A randomized trial of intraarterial treatment for acute ischemic stroke. N. Engl. J. Med. 372, 11–20.
6. Bustamante A., Giralt D., García-Bonilla L., Campos M., Rosell A. and Montaner J. (2012) Citicoline in pre-clinical animal models of stroke: a meta-analysis shows the optimal neuroprotective profile and the missing steps for jumping into a stroke clinical trial. J. Neurochem. 123, 217–225.
7. Button K. S. (2016) Statistical rigor and the perils of chance. eNeuro, 3, 1–4.
8. Button K. S., Ioannidis J. P., Mokrysz C., Nosek B. A., Flint J., Robinson E. S. and Munafo M. R. (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat. Rev. Neurosci. 14, 365–376.
9. Campbell B. C., Mitchell P. J., Kleinig T. J. et al. (2015) Endovascular therapy for ischemic stroke with perfusion-imaging selection. N. Engl. J. Med. 372, 1009–1018.
10. Chalmers I. and Glasziou P. (2009) Avoidable waste in the production and reporting of research evidence. The Lancet 374, 86–89.
11. Chalmers I., Bracken M. B., Djulbegovic B., Garattini S., Grant J., Gülmezoglu A. M., Howells D. W., Ioannidis J. P. A. and Oliver S. (2014) How to increase value and reduce waste when research priorities are set. The Lancet 383, 156–165.
12. Chan A.-W., Song F., Vickers A., Jefferson T., Dickersin K., Gøtzsche P. C., Krumholz H. M., Ghersi D. and van der Worp H. B. (2014) Increasing value and reducing waste: addressing inaccessible research. Lancet 383, 257–266.
13. Deer B. (2011a) How the case against the MMR vaccine was fixed. BMJ 342, c5347.
14. Deer B. (2011b) Pathology reports solve “new bowel disease” riddle. BMJ 343, d6823.
15. Deer B. (2011c) Secrets of the MMR scare. How the vaccine crisis was meant to make money. BMJ 342, c5258.
16. Deer B. (2011d) Secrets of the MMR scare. The Lancet's two days to bury bad news. BMJ 342, c7001.
17. Editorial (2009) Identity crisis. Nature 457, 935–936.
18. Fang F. C., Steen R. G. and Casadevall A. (2012) Misconduct accounts for the majority of retracted scientific publications. Proc. Natl Acad. Sci. 109, 17028–17033.
19. Flaherty D. K. (2011) The vaccine-autism connection: a public health crisis caused by unethical medical practices and fraudulent science. Ann. Pharmacother. 45, 1302–1304.
20. García-Bonilla L., Campos M., Giralt D., Salat D., Chacón P., Hernández-Guillamon M., Rosell A. and Montaner J. (2012) Evidence for the efficacy of statins in animal stroke models: a meta-analysis. J. Neurochem. 122, 233–243.
21. Glasziou P., Altman D. G., Bossuyt P., Boutron I., Clarke M., Julious S., Michie S., Moher D. and Wager E. (2014) Reducing waste from incomplete or unusable reports of biomedical research. Lancet 383, 267–276.
22. Goyal M., Demchuk A. M., Menon B. K. et al. (2015) Randomized assessment of rapid endovascular treatment of ischemic stroke. N. Engl. J. Med. 372, 1019–1030.
23. Goyal M., Menon B. K., van Zwam W. H. et al. (2016) Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. The Lancet 387, 1723–1731.
24. Hausmann L., Murphy S. and on behalf of the Publication Committee of the ISN (2016) The challenges for scientific publishing, 60 years on. J. Neurochem. 139 (Suppl. 2), 280–287.
25. Higgins J. P. T. and Green S. (eds). (2011) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from http://handbook.cochrane.org.
26. Holman C., Piper S. K., Grittner U., Diamantaras A. A., Kimmelman J., Siegerink B. and Dirnagl U. (2016) Where have all the rodents gone? the effects of attrition in experimental research on cancer and stroke. PLoS Biol. 14, e1002331–1002312.
27. Hooker B. S. (2014) Measles-mumps-rubella vaccination timing and autism among young African American boys: a reanalysis of CDC data. Transl. Neurodegener 3, 16.
28. Horton R. (2004) A statement by the editors of The Lancet. Lancet 363, 820–821.
29. Ioannidis J. P. A., Greenland S., Hlatky M. A., Khoury M. J., Macleod M. R., Moher D., Schulz K. F. and Tibshirani R. (2014) Increasing value and reducing waste in research design, conduct, and analysis. Lancet 383, 166–175.
30. Iqbal S. A., Wallach J. D., Khoury M. J., Schully S. D. and Ioannidis J. P. A. (2016) Reproducible Research Practices and Transparency across the Biomedical Literature. PLoS Biol. 14, e1002333–1002313.
31. Jain A., Marshall J., Buikema A., Bancroft T., Kelly J. P. and Newschaffer C. J. (2015) Autism occurrence by MMR vaccine status among US children with older siblings with and without autism. JAMA 313, 1534–1540.
32. Jovin T. G., Chamorro A., Cobo E. et al. (2015) Thrombectomy within 8 hours after symptom onset in ischemic stroke. N. Engl. J. Med. 372, 2296–2306.
33. Kerman A., Liu H.-N., Croul S., Bilbao J., Rogaeva E., Zinman L., Robertson J. and Chakrabartty A. (2010) Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta Neuropathol. 119, 335–344.
34. Kilkenny C., Browne W. J., Cuthill I. C., Emerson M. and Altman D. G. (2010) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412.
35. Landis S. C., Amara S. G., Asadullah K. et al. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187–191.
36. Llovera G. and Liesz A. (2016) The next step in translational research: lessons learned from the first preclinical randomized controlled trial. J. Neurochem. 139(Suppl. 2), 271–279.
37. Llovera G., Roth S., Plesnila N., Veltkamp R. and Liesz A. (2014) Modeling stroke in mice: permanent coagulation of the distal middle cerebral artery. J. Vis. Exp. (89): e51729. DOI: 10.3791/51729.
38. Llovera G., Hofmann K., Roth S. et al. (2015) Results of a preclinical randomized controlled multicenter trial (pRCT): anti-CD49d treatment for acute brain ischemia. Sci. Transl. Med. 7, 299ra121.
39. Ludolph A. C., Bendotti C., Blaugrund E. et al. (2010) Guidelines for preclinical animal research in ALS/MND: a consensus meeting. Amyotrophic Lateral Sclerosis 11, 38–45.
40. Mackenzie I. R. A., Bigio E. H., Ince P. G. et al. (2007) Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann. Neurol. 61, 427–434.
41. Macleod M. R., Michie S., Roberts I., Dirnagl U., Chalmers I., Ioannidis J. P. A., Salman R. A.-S., Chan A.-W. and Glasziou P. (2014) Biomedical research: increasing value, reducing waste. The Lancet 383, 101–104.
42. Magen I. and Chesselet M. F. (2010) Genetic mouse models of Parkinson's disease The state of the art. Prog. Brain Res. 184, 53–87.
43. Masters J. R. (2012) Cell-line authentication: end the scandal of false cell lines. Nature 492, 186.
44. Moher D., Glasziou P., Chalmers I., Nasser M., Bossuyt P. M. M., Korevaar D. A., Graham I. D., Ravaud P. and Boutron I. (2016) Increasing value and reducing waste in biomedical research: who's listening? Lancet 387, 1573–1586.
45. Murch S. H., Anthony A., Casson D. H. et al. (2004) Retraction of an interpretation. The Lancet 363, 750–751.
46. Murphy S. P. and Murphy A. N. (2010) Pre-clinical systematic review. J. Neurochem. 115, 805.
47. Nieuwenhuis S., Forstmann B. U. and Wagenmakers E.-J. (2011) Erroneous analyses of interactions in neuroscience: a problem of significance. Nature Publishing Group 14, 1105–1107.
48. Nosek B. A., Alter G., Banks G. C. et al. (2015) Promoting an open research culture. Science (New York, NY) 348, 1422–1425.
49. Obokata H., Sasai Y., Niwa H. et al. (2014a) Bidirectional developmental potential in reprogrammed cells with acquired pluripotency. Nature 505, 676–680.
50. Obokata H., Sasai Y., Niwa H. et al. (2014b) Retraction: bidirectional developmental potential in reprogrammed cells with acquired pluripotency. Nature 511, 112.
51. Peelaerts W. and Baekelandt V. (2016) ɑ-Synuclein strains and the variable pathologies of synucleinopathies. J. Neurochem. 139 (Suppl. 1), 256–274.
52. Rosen D. R., Siddique T., Patterson D. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62.
53. Saver J. L., Goyal M., Bonafe A. et al. (2015) Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. N. Engl. J. Med. 372, 2285–2295.
54. Schenk D., Barbour R., Dunn W. et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400, 173–177.
55. Schonberger K., Ludwig M. S., Wildner M. and Weissbrich B. (2013) Epidemiology of subacute sclerosing panencephalitis (SSPE) in Germany from 2003 to 2009: a risk estimation. PLoS ONE 8, e68909.
56. Scott S., Kranz J. E., Cole J. et al. (2009) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotrophic Lateral Sclerosis 9, 4–15.
57. Sevigny J., Chiao P., Bussière T. et al. (2016) The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 537, 50–56.
58. Taylor L. E., Swerdfeger A. L. and Eslick G. D. (2014) Vaccines are not associated with autism: an evidence-based meta-analysis of case-control and cohort studies. Vaccine 32, 3623–3629.
59. The Editors of the Lancet. (2010) RetractionöIleal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. The Lancet, 375, 445.
60. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581–1587.
61. Vines T. H., Andrew R. L., Bock D. G. et al. (2013) Mandated data archiving greatly improves access to research data. FASEB J. 27, 1304–1308.
62. Volpicelli-Daley L. A., Kirik D., Stoyka L. E., Standaert D. G. and Harms A. S. (2016) How can rAAV-α -synuclein and the fibril a-synuclein `models advance our understanding of Parkinson’s disease? J. Neurochem. 139 (Suppl. 1), 131–155.
63. White A. T. and Murphy A. N. (2010) Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review. J. Neurochem. 115, 845–853.
64. Yu M., Selvaraj S. K., Liang-Chu M. M. Y. et al. (2015) A resource for cell line authentication, annotation and quality control. Nature 520, 307–311.